Learnings from Evolut Low Risk 5-year and SMART 2-year trials : from evidence to practice

At EuroPCR 2025, Angela McInerney, Didier Tchétché, and Ole De Backer discuss key results from the SMART and Evolut Low Risk trials. The SMART trial compared balloon-expandable and self-expanding valves in small annulus patients, showing better hemodynamics with the Evolut platform at 2 years. The Evolut Low Risk trial confirmed stable hemodynamic performance of Evolut versus surgery at 5 years in low-risk patients.

They also compare these findings to the NOTION trial’s 10-year data, explore the impact of pacemakers on outcomes, and consider how this evidence may guide treatment of severe aortic stenosis in younger, low-risk patients. With new guidelines expected, these results could influence future clinical practice.

Watch the full roundtable to learn more.

This interview was filmed at EuroPCR 2025: see more videos here.